29.12.2020 – AC Immune announced the receipt of grants by Target ALS
AC Immune, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, received a highly competitive grant awarded by Target ALS. The grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital. It will accelerate the development of the Company’s proprietary immuno-assays to detect disease-associated forms of TAR DNA-binding protein 43 (TDP-43) in cerebrospinal fluid and blood samples. The pathological aggregation of TDP-43 is strongly associated with motor and cognitive decline and episodic memory loss in several neurodegenerative diseases
AC Immune’s SupraAntigen-based detection assays for aggregation-prone forms of TDP-43 in biofluids have the potential to serve as an early-stage diagnostic that may enable the development of precision medicine approaches for these diseases as well as Alzheimer’s disease (AD), where pathological aggregation of TDP-43 has emerged as an important co-pathology linked to disease severity.